RARE - Company ID 0001515673
The table below shows Ultragenyx Pharmaceutical Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$466.00M | -$414.00M | -$475.00M | -$380.46M | -$338.69M | -$132.22M |
| Capital expenditure | $6.00M | $7.00M | $44.00M | $116.12M | $73.09M | $43.91M |
| Investing cash flow | $236.00M | -$18.00M | $168.00M | -$291.65M | -$195.37M | -$179.12M |
| Dividends paid | - | - | - | - |
Ultragenyx Pharmaceutical Inc. reported operating cash flow of -$466.00M for fiscal year 2025. That is down 12.6% from -$414.00M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$160.97M (FY 2016) to -$466.00M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $478.00M | $399.00M | $388.00M | $501.21M | $118.55M | $600.27M |